Diabetic macular edema

Risuteganib met its primary endpoints in two Phase 2b trials. Allegro is now preparing for a Phase 3 clinical study in subjects with DME, anticipated to begin in the first half of 2019. Read more about the completed Phase 2b studies.
View study on ClinicalTrials.gov

Dry age-related macular degeneration (AMD)

Allegro is also conducting a Phase 2a study of patients with intermediate, non-exudative AMD (dry AMD). Results are anticipated in the second half of 2019.
View study on ClinicalTrials.gov